Literature DB >> 3288467

Atenolol and sustained release nifedipine alone and in combination in hypertension. A randomised, double-blind, crossover study.

J L Anderton1, B D Vallance, N N Stanley, P F Crowe, B Mittra, W H Perks.   

Abstract

In this randomised, double-blind, crossover trial, the efficacy in hypertension of atenolol and nifedipine as single agents or in combination was compared. 81 patients with mild to moderate essential hypertension (sitting diastolic blood pressure 100-120 mm Hg, aged 20-70 years) from 6 outpatient clinics entered the study. By use of a Latin-square design, patients received, in randomised fashion, sustained release nifedipine 20mg twice daily, atenolol 50mg in the morning and then placebo in the evening, or sustained release nifedipine 20mg plus atenolol 50mg in the morning and then placebo in the evening. Each schedule was followed for 4 weeks. All treatments lowered systolic and diastolic blood pressure in the supine and standing positions compared with pretreatment values. The combination regimen significantly reduced supine and standing systolic (p less than 0.01 and p less than 0.001, respectively) and diastolic (p less than 0.001) blood pressure compared with nifedipine alone, and it also significantly reduced supine and standing systolic (p less than 0.01 and p less than 0.03, respectively) and diastolic (p less than 0.01) blood pressure compared with atenolol alone. Heart rate was significantly decreased by atenolol and the combination compared with nifedipine alone. 15 patients withdrew because of side effects: 9 during nifedipine treatment, 2 during atenolol treatment and 4 during combination treatment. Side effects were typical of those associated with nifedipine or atenolol. Flushes and hot sweats, which were frequent with nifedipine, were significantly less (p less than 0.001) with atenolol or the combination.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3288467     DOI: 10.2165/00003495-198800354-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  5 in total

1.  Dose response for blood pressure and degree of cardiac beta-blockade with atenolol.

Authors:  A J Marshall; D W Barritt; S Heaton; J D Harry
Journal:  Postgrad Med J       Date:  1979-09       Impact factor: 2.401

2.  A comparative study of atenolol/nifedipine and atenolol/diuretic in hypertension.

Authors:  K G Edwards; J A Tweed; P A Saul; F W Wright
Journal:  Pharmatherapeutica       Date:  1986

3.  Atenolol plus nifedipine for mild to moderate systemic hypertension after fixed doses of either agent alone.

Authors:  A R Daniels; L H Opie
Journal:  Am J Cardiol       Date:  1986-04-15       Impact factor: 2.778

4.  Nitrendipine and atenolol: comparison and combination in the treatment of arterial hypertension.

Authors:  O de Divitiis; M Petitto; S Di Somma; M Galderisi; B Villari; M Santomauro; S Fazio
Journal:  Arzneimittelforschung       Date:  1985

Review 5.  Combination therapy with beta-adrenoceptor blockers and calcium antagonists.

Authors:  H J Dargie
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

  5 in total
  4 in total

Review 1.  Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension.

Authors:  M Ruzicka; F H Leenen
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Fixed-dose combination antihypertensive drugs. Do they have a role in rational therapy?

Authors:  D A Sica
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

Review 3.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 4.  [Atenolol/nifedipine combination: efficacy and tolerability of low dose synergistic bitherapy in the treatment of arterial hypertension].

Authors:  A Krivitzky; G Nguyen; Y Gaudouen; M Legrand; R Cohen
Journal:  Drugs       Date:  1998       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.